These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 8306591)

  • 1. Different acute and chronic effects of acipimox treatment on glucose and lipid metabolism in patients with type 2 diabetes.
    Saloranta C; Groop L; Ekstrand A; Franssila-Kallunki A; Eriksson J; Taskinen MR
    Diabet Med; 1993 Dec; 10(10):950-7. PubMed ID: 8306591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effects of a sustained-release preparation of acipimox on dyslipidemia and glucose metabolism in non-insulin-dependent diabetes mellitus.
    Davoren PM; Kelly W; Gries FA; Hubinger A; Whately-Smith C; Alberti KG
    Metabolism; 1998 Mar; 47(3):250-6. PubMed ID: 9500558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of an antilipolytic agent (acipimox) on the insulin resistance of lipid and glucose metabolism in hypertriglyceridaemic patients.
    Saloranta C; Groop L; Ekstrand A; Franssila-Kallunki A; Taskinen MR
    Acta Diabetol; 1994 Apr; 31(1):6-13. PubMed ID: 8043900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double blind study of the effect of acipimox on serum lipids, blood glucose control and insulin action in non-obese patients with type 2 diabetes mellitus.
    Fulcher GR; Catalano C; Walker M; Farrer M; Thow J; Whately-Smith CR; Alberti KG
    Diabet Med; 1992 Dec; 9(10):908-14. PubMed ID: 1478035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic effects of suppression of nonesterified fatty acid levels with acipimox in obese NIDDM subjects.
    Fulcher GR; Walker M; Catalano C; Agius L; Alberti KG
    Diabetes; 1992 Nov; 41(11):1400-8. PubMed ID: 1397716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic consequences of sustained suppression of free fatty acids by acipimox in patients with NIDDM.
    Saloranta C; Taskinen MR; Widen E; Härkönen M; Melander A; Groop L
    Diabetes; 1993 Nov; 42(11):1559-66. PubMed ID: 8405695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pronounced blood glucose-lowering effect of the antilipolytic drug acipimox in noninsulin-dependent diabetes mellitus patients during a 3-day intensified treatment period.
    Worm D; Henriksen JE; Vaag A; Thye-Rønn P; Melander A; Beck-Nielsen H
    J Clin Endocrinol Metab; 1994 Mar; 78(3):717-21. PubMed ID: 8126147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the antilipolytic nicotinic acid analogue acipimox on whole-body and skeletal muscle glucose metabolism in patients with non-insulin-dependent diabetes mellitus.
    Vaag A; Skött P; Damsbo P; Gall MA; Richter EA; Beck-Nielsen H
    J Clin Invest; 1991 Oct; 88(4):1282-90. PubMed ID: 1918378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of hepatic glucose production by non-esterified fatty acids in type 2 (non-insulin-dependent) diabetes mellitus.
    Saloranta C; Franssila-Kallunki A; Ekstrand A; Taskinen MR; Groop L
    Diabetologia; 1991 Jun; 34(6):409-15. PubMed ID: 1884899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of prolonged Acipimox treatment on glucose and lipid metabolism and on in vivo insulin sensitivity in patients with non-insulin dependent diabetes mellitus.
    Vaag AA; Beck-Nielsen H
    Acta Endocrinol (Copenh); 1992 Oct; 127(4):344-50. PubMed ID: 1449046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute metabolic and hormonal responses to the inhibition of lipolysis in non-obese patients with non-insulin-dependent (type 2) diabetes mellitus: effects of acipimox.
    Fulcher GR; Walker M; Catalano C; Farrer M; Alberti KG
    Clin Sci (Lond); 1992 May; 82(5):565-71. PubMed ID: 1317767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of lipoprotein lipid composition in type II diabetic patients with concomitant hyperlipoproteinemia by acipimox treatment. Results of a multicenter trial.
    Koev D; Zlateva S; Susic M; Babic D; Profozic V; Skrabalo Z; Langrová H; Cvrkalová AL; Rajecová E; Klimes I
    Diabetes Care; 1993 Sep; 16(9):1285-90. PubMed ID: 8404433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of changes in plasma nonesterified fatty acid levels on oxidative metabolism during moderate exercise in patients with non-insulin-dependent diabetes mellitus.
    Akanji AO; Osifo E; Kirk M; Hockaday TD
    Metabolism; 1993 Apr; 42(4):426-34. PubMed ID: 8487664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid metabolism and insulin resistance in cirrhosis.
    Kaye GL; Kruszynska YT; Harry DS; Heslop K; Johnston DG; McIntyre N
    J Hepatol; 1994 Jun; 20(6):782-91. PubMed ID: 7930479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of an acute decrease in non-esterified fatty acid levels on muscle glucose utilization and forearm indirect calorimetry in lean NIDDM patients.
    Piatti PM; Monti LD; Davis SN; Conti M; Brown MD; Pozza G; Alberti KG
    Diabetologia; 1996 Jan; 39(1):103-12. PubMed ID: 8720610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperlipidaemia is associated with increased insulin-mediated glucose metabolism, reduced fatty acid metabolism and normal blood pressure in transgenic mice overexpressing human apolipoprotein C1.
    Koopmans SJ; Jong MC; Que I; Dahlmans VE; Pijl H; Radder JK; Frölich M; Havekes LM
    Diabetologia; 2001 Apr; 44(4):437-43. PubMed ID: 11357474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Acipimox on the metabolism of free fatty acids and very low lipoprotein triglyceride.
    Hannah JS; Bodkin NL; Paidi MS; Anh-Le N; Howard BV; Hansen BC
    Acta Diabetol; 1995 Dec; 32(4):279-83. PubMed ID: 8750769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral and hepatic insulin sensitivity in non-insulin-dependent diabetes mellitus: effect of nonesterified fatty acids.
    Walker M; Agius L; Orskov H; Alberti KG
    Metabolism; 1993 May; 42(5):601-8. PubMed ID: 8492715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of lipolysis during acute GH exposure increases insulin sensitivity in previously untreated GH-deficient adults.
    Segerlantz M; Bramnert M; Manhem P; Laurila E; Groop LC
    Eur J Endocrinol; 2003 Dec; 149(6):511-9. PubMed ID: 14640991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of plasma non-esterified fatty acids during exercise in type 2 diabetes mellitus.
    Berrish TS; Elliott C; Cooper BG; Reed JW; Orskov H; Alberti KG; Walker M
    Diabet Med; 1993 Mar; 10(2):152-8. PubMed ID: 8458192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.